Inozyme Pharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 59
- Market Cap
- $367.7M
- Website
- http://www.inozyme.com
- Introduction
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best
Tenpoint Therapeutics and Visus Therapeutics merge to focus on ophthalmic therapeutics, including BRIMOCHOL™ PF for presbyopia, with a US launch planned for 1H 2026. The merger involves a syndicate of investors and appoints Henric Bjarke as CEO, aiming to advance innovative treatments for presbyopia, cataracts, and geographic atrophy.
Tenpoint and Visus Complete Merger
Tenpoint Therapeutics and Visus Therapeutics merged, focusing on ophthalmology with Brimochol PF for presbyopia, TPT-161 for cataracts, and TPT-005 for geographic atrophy. Brimochol PF, nearing FDA approval, targets a 2026 U.S. launch. The merger aims to advance innovative ophthalmic treatments.
Tenpoint Therapeutics Ltd. and Visus Therapeutics Merge to Advance Ophthalmic Treatments
Tenpoint Therapeutics and Visus Therapeutics merge, focusing on BRIMOCHOL™ PF, a presbyopia-correcting eye drop, aiming for US launch in 1H 2026. The merger combines expertise and funding to advance ophthalmic treatments, including BRIMOCHOL™ PF, TPT-161 for cataracts, and TPT-005 for geographic atrophy, under new CEO Henric Bjarke.
© Copyright 2025. All Rights Reserved by MedPath